Litfulo (ritlecitinib): Updated recommendations to minimise the risks of major adverse cardiovascular events, malignancy, venous thromboembolism, serious infections, and mortality
10/08/2026
Medicines for human use
Direct healthcare professional communication (DHPC)
Important Safety Information from Pfizer Healthcare Ireland UC regarding Litfulo (ritlecitinib): updated recommendations to minimise the risks of major adverse cardiovascular events, malignancy, venous thromboembolism, serious infections, and mortality